# The State of AI in Clinical Trials — 2026

**K-Dense Science Lab — Market Analysis Division**
*Data snapshot: 2026-09-15T17:56:58Z · Registry: ClinicalTrials.gov API v2 · Studies analyzed: 4,250*

---

## 1. Executive Summary

Artificial intelligence has moved from curiosity to standard infrastructure in clinical research — but it has **not** yet transformed how trials themselves are regulated and phased. We analyzed every ClinicalTrials.gov study whose intervention description references "artificial intelligence" or "machine learning" (4,250 studies, ~0.7% of the 602,897-study registry).

**Five findings that matter:**

1. **The curve is still steepening.** Annual AI/ML trial postings grew from 137 (2019) to 712 (2024) — and 2026 has already logged **933 postings with 3.5 months remaining**, 15% above all of 2025 (811). Seven posting-years from the 2019 baseline (the table's first year): 137 → 933, a 6.8× increase.

2. **AI tools are mostly studied *observationally*.** 55.6% of AI/ML-flagged studies are observational; only 44.4% are interventional. Strikingly, just **80 interventional studies carry any formal phase designation** (single, combination, or early Phase 1) — 1.9% of the cohort. AI is being validated like a diagnostic instrument, not developed like a drug.

3. **Academic medicine, not pharma, is running the field.** 85% of studies are led by non-industry sponsors. The top AI-trial producers are academic hospitals — National Taiwan University Hospital (43), Mayo Clinic (41), Cairo University (38), Sun Yat-sen University (38). Industry leads only 450 studies (10.6%).

4. **China has pulled even with the United States.** Studies with sites in China: 807. United States: 783. The next tier (Italy 240, Türkiye 232, France 203) is not close. Any market map of clinical AI that centers only on FDA-land is missing half the field.

5. **Oncology and cardiology are the beachheads.** Leading studied conditions: breast cancer (87), heart failure (77), coronary artery disease (51), lung cancer (45), prostate cancer (44). A distinct sub-field — **443 studies (10.4%)** — names AI/ML itself as the intervention under test (reproducible via an `AREA[InterventionName]` count on the same query; see `analysis/stats.json`), the clearest signal of an emerging "AI as medical product" pipeline.

**Implication for buyers:** the commercial opportunity in clinical AI is shifting from algorithm development to *validation infrastructure* — trial design, endpoint standardization, and regulatory-grade evidence generation for tools that are currently being validated ad hoc, without phased pathways.

---

## 2. Methodology

**Source.** ClinicalTrials.gov API v2 (`https://clinicaltrials.gov/api/v2/studies`), the authoritative registry of the U.S. National Library of Medicine.

**Query.** `query.intr = "artificial intelligence" OR "machine learning"` — full-text match on intervention descriptions. All 4,250 matching records retrieved via paginated field-pruned requests (500/page, 9 pages) on 2026-09-15.

**Pipeline.** Deterministic, zero-dependency Python (`analysis/fetch_build.py`, stdlib only). Raw records archived as JSONL; flattened CSV (14 data columns per study; the raw JSONL archive is field-pruned to the protocol fields used here); statistics serialized to `analysis/stats.json`.

**Verification.** Every headline statistic was recomputed from the flattened CSV through an independent code path and cross-checked against `stats.json` (9/9 checks passed; 4,250 unique NCT IDs, no duplicates).

**Caveats (disclosed, quantified where possible).**
- The intervention-text query is a *lower bound* on true adoption: trials using AI without naming it (e.g., "automated segmentation," "algorithm-guided") are not captured. Conversely, incidental AI mentions in intervention descriptions can inflate counts, so neither the level nor the slope has a fixed sign — both are sensitive to vocabulary coverage.
- Enrollment is reported for 4,248 of 4,250 studies (2 missing); enrollment statistics exclude those 2.
- `posting_by_year` uses study first-posting date; retrospective re-registrations appear in their posting year.
- 2026 figures cover 1 Jan–15 Sep (partial year).
- Country counts are study-level (a study with sites in 5 countries counts 5 times).
- 793 studies (18.7%) carry `UNKNOWN` overall status — a known registry data-quality artifact for older records; we report registry statuses verbatim rather than imputing.

---

## 3. Findings

### 3.1 Growth: the adoption curve has not bent yet

| Year | Postings | | Year | Postings |
|------|----------|-|------|----------|
| 2019 | 137 | | 2023 | 487 |
| 2020 | 246 | | 2024 | 712 |
| 2021 | 353 | | 2025 | 811 |
| 2022 | 428 | | **2026 (to Sep 15)** | **933** |

Even at constant H2 velocity, 2026 will exceed 1,200 postings — a fourth consecutive record year and roughly 8.8× the 2019 volume (933 posted to date = 6.8×). The registry-wide share is still small (0.7%), which is precisely the headroom story: AI trialization is early by volume, mature by momentum.

### 3.2 Lifecycle status: a cohort that is completing its first cycle

| Status | Studies | Share |
|---|---|---|
| COMPLETED | 1,359 | 32.0% |
| RECRUITING | 958 | 22.5% |
| UNKNOWN (legacy records) | 793 | 18.7% |
| NOT_YET_RECRUITING | 650 | 15.3% |
| ACTIVE_NOT_RECRUITING | 255 | 6.0% |
| ENROLLING_BY_INVITATION | 123 | 2.9% |
| WITHDRAWN / TERMINATED / other | 112 | 2.6% |

A completed cohort of 1,359 studies now exists — large enough for systematic evidence synthesis (effectiveness of AI-guided care vs. standard pathways). This is an open, low-cost research product in itself.

### 3.3 The "no phased pathway" gap

Study types: OBSERVATIONAL 2,363 · INTERVENTIONAL 1,886 · EXPANDED_ACCESS 1.

Of the 1,886 interventional studies, **80 carry any formal phase designation** (Ph1 7, Ph1/2 6, Ph2 31, Ph2/3 1, Ph3 9, Ph4 20, ePh1 6 — counting any phase designation, including combinations and early Phase 1). The remaining 1,806 interventional studies (95.8%) are registered "NA" — device-style or feasibility-style evaluations without the phased evidence ladder that drugs follow. For scale: registry-wide, 51.4% of the 460,125 interventional studies are non-phased (236,639) — within the AI cohort it is 95.8%, nearly double the registry baseline.

This is the report's central structural finding: **clinical AI currently lacks a regulatory evidence pathway of its own and is borrowing inadequate frameworks from two sides** — drug-style phases (rare, 80 studies) and observational validation (dominant, 55.6%). Vendors and regulators are filling the vacuum ad hoc (FDA's Predetermined Change Control Plans, EU AI Act high-risk classification). Whoever standardizes "AI trial methodology" owns a category.

### 3.4 Geography: a two-superpower system

| Country | Studies w/ sites |
|---|---|
| China | 807 |
| United States | 783 |
| Italy | 240 |
| Türkiye | 232 |
| France | 203 |
| Spain | 195 |

China's hospital-network scale (dozens of academic systems at 20–43 studies each) has produced parity with the U.S. — with different regulatory thresholds on both sides. Multinational clinical-AI vendors face a two-regime evidence problem.

### 3.5 Sponsors: academia builds, industry waits

Sponsor classes: OTHER (academic/non-profit) 3,625 · INDUSTRY 450 · government 161. Top producers are academic medical centers. Industry's 10.6% lead-sponsor share says pharma is still in *watch-and-license* mode — the M&A and partnership wave typically follows validation-phase maturation, and 80 phased studies say that wave has not started.

### 3.6 Therapeutic-area heat map

Top studied conditions: Artificial Intelligence (as condition; 288 across spelling variants), Breast Cancer 87, Heart Failure 77, Machine Learning (as condition) 62, Coronary Artery Disease 51, Lung Cancer 45, Anxiety 44, Prostate Cancer 44, Colorectal Cancer 42, Cancer 41, Sepsis 40, Stroke 40, Atrial Fibrillation 37, Diabetic Retinopathy 37.

Pattern: **imaging-rich, outcome-quantifiable specialties lead** (oncology, cardiology, ophthalmology). Psychiatry appears via anxiety/depression cohorts — mostly digital-therapeutic adjuncts.

### 3.7 Scale profile

Median enrollment: 250 participants · p90: 4,882 · mean: 30,274 (mean ≫ median pulled by mega-cohort observational data-mining studies). The typical AI trial is a single-dataset validation at moderate scale — consistent with the missing phase ladder.

---

## 4. Market Implications (for syndication buyers)

1. **Validation infrastructure is the gap.** 1,886 interventional AI studies with only 80 phased → methodology-as-a-service (protocol design, endpoint selection, regulatory strategy) is a natural adjacent market.
2. **Evidence synthesis is productizable now.** 1,359 completed trials = immediately harvestable corpus for comparative-effectiveness reports per therapeutic area. (Natural follow-on deliverable; K-Dense can produce per-vertical cuts from this same dataset.)
3. **Two-regime go-to-market.** China/US parity means any clinical-AI commercialization plan needs dual evidence strategies; EU (France/Spain/Italy = 638 studies combined) is the third bloc.
4. **Timing signal for pharma BD.** Industry lead share at 10.6% against 6.8× growth since 2019 is, in our interpretation, a pre-consolidation shape — buy-side teams may see the licensing window open as the completed-cohort evidence base matures.

---

## 5. Reproducibility

```bash
cd analysis
python3 fetch_build.py    # refetches live data, rebuilds CSV + stats.json
```

Requirements: Python 3.9+, internet access, no API keys. Runtime ≈ 30 s. The pipeline is deterministic given the live registry; date-stamped outputs make snapshots comparable over time.

## 6. File Manifest

| File | Description |
|---|---|
| `data/ai_trials_raw.jsonl` | 4,250 raw registry records (field-pruned), 5.2 MB |
| `data/ai_trials_flat.csv` | 14-field flattened table, 4,250 rows |
| `analysis/fetch_build.py` | Fetch + flatten + stats pipeline (stdlib only) |
| `analysis/stats.json` | All computed statistics, machine-readable |
| `README.md` | This report |
| `syndication/executive-abstract.md` | 1-page abstract for LinkedIn/blog syndication |
| `syndication/channel-plan.md` | Distribution-channel recommendation + owner-gated action list |
| `syndication/pricing-tiers.md` | Recommended pricing if sold as syndicated market report |

## 7. License & Attribution

Data: ClinicalTrials.gov (NLM/NIH), public domain. Analysis: K-Dense Science Lab, 2026. Citation: *K-Dense Science Lab, "The State of AI in Clinical Trials — 2026," Sept 2026 dataset + report.*
